Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP418256.RAOKUSa6HiqGeWSrU2PDt12TYJ4skr_CdmLf8jw3CU0bU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP418256.RAOKUSa6HiqGeWSrU2PDt12TYJ4skr_CdmLf8jw3CU0bU130_assertion type Assertion NP418256.RAOKUSa6HiqGeWSrU2PDt12TYJ4skr_CdmLf8jw3CU0bU130_head.
- NP418256.RAOKUSa6HiqGeWSrU2PDt12TYJ4skr_CdmLf8jw3CU0bU130_assertion description "[The combination of IFN-gamma and CaM antagonists, including tamoxifen, may be a potential therapeutic modality for cholangiocarcinoma and possibly other malignancies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP418256.RAOKUSa6HiqGeWSrU2PDt12TYJ4skr_CdmLf8jw3CU0bU130_provenance.
- NP418256.RAOKUSa6HiqGeWSrU2PDt12TYJ4skr_CdmLf8jw3CU0bU130_assertion evidence source_evidence_literature NP418256.RAOKUSa6HiqGeWSrU2PDt12TYJ4skr_CdmLf8jw3CU0bU130_provenance.
- NP418256.RAOKUSa6HiqGeWSrU2PDt12TYJ4skr_CdmLf8jw3CU0bU130_assertion SIO_000772 14578204 NP418256.RAOKUSa6HiqGeWSrU2PDt12TYJ4skr_CdmLf8jw3CU0bU130_provenance.
- NP418256.RAOKUSa6HiqGeWSrU2PDt12TYJ4skr_CdmLf8jw3CU0bU130_assertion wasDerivedFrom befree-2016 NP418256.RAOKUSa6HiqGeWSrU2PDt12TYJ4skr_CdmLf8jw3CU0bU130_provenance.
- NP418256.RAOKUSa6HiqGeWSrU2PDt12TYJ4skr_CdmLf8jw3CU0bU130_assertion wasGeneratedBy ECO_0000203 NP418256.RAOKUSa6HiqGeWSrU2PDt12TYJ4skr_CdmLf8jw3CU0bU130_provenance.